|
US5116817A
(en)
|
1982-12-10 |
1992-05-26 |
Syntex (U.S.A.) Inc. |
LHRH preparations for intranasal administration
|
|
US4476116A
(en)
|
1982-12-10 |
1984-10-09 |
Syntex (U.S.A.) Inc. |
Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
|
|
US5244792A
(en)
|
1984-04-06 |
1993-09-14 |
Chiron Corporation |
Expression of recombinant glyoprotein B from herpes simplex virus
|
|
JPH0668B2
(ja)
|
1985-08-30 |
1994-01-05 |
財団法人化学及血清療法研究所 |
単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5804413A
(en)
|
1992-07-31 |
1998-09-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
|
GB9415369D0
(en)
|
1994-07-29 |
1994-09-21 |
Lynxvale Ltd |
Mutant virus
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6071742A
(en)
|
1997-03-05 |
2000-06-06 |
Board Of Regents Of The University Of Nebraska |
Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
|
|
WO1998040475A1
(en)
|
1997-03-11 |
1998-09-17 |
Abbott Laboratories |
Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
US6391452B1
(en)
|
1997-07-18 |
2002-05-21 |
Bayer Corporation |
Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
|
|
AU8605598A
(en)
|
1997-07-31 |
1999-02-22 |
University Of Pittsburgh |
Targeted hsv vectors
|
|
US6989435B2
(en)
|
1997-09-11 |
2006-01-24 |
Cambridge University Technical Services Ltd. |
Compounds and methods to inhibit or augment an inflammatory response
|
|
CA2315251A1
(en)
|
1997-12-17 |
1999-06-24 |
Immunex Corporation |
Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
US7112324B1
(en)
|
1998-04-21 |
2006-09-26 |
Micromet Ag |
CD 19×CD3 specific polypeptides and uses thereof
|
|
EP0953639A1
(en)
|
1998-04-30 |
1999-11-03 |
Boehringer Ingelheim International GmbH |
FAPalpha-specific antibody with improved producibility
|
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
|
EP1002864A1
(en)
|
1998-11-10 |
2000-05-24 |
Universita' degli studi di Bologna |
HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
CZ302706B6
(cs)
|
1998-12-23 |
2011-09-14 |
Pfizer Inc. |
Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US6897057B1
(en)
|
1999-08-31 |
2005-05-24 |
The General Hospital Corporation |
Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
|
|
HK1047109A1
(zh)
|
1999-10-15 |
2003-02-07 |
University Of Massachusetts |
作为指定基因干预工具的rna干预轨迹基因
|
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート，エルエルシー |
Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
|
|
EP1268550A2
(en)
|
2000-03-17 |
2003-01-02 |
Boehringer Ingelheim Pharma KG |
Human fap-alpha-specific antibodies
|
|
ES2336887T5
(es)
|
2000-03-30 |
2019-03-06 |
Whitehead Inst Biomedical Res |
Mediadores de interferencia por ARN específicos de secuencias de ARN
|
|
CA2429814C
(en)
|
2000-12-01 |
2014-02-18 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
EP1381280B1
(en)
|
2001-03-27 |
2011-05-11 |
Catherex, Inc. |
Viral vectors and their use in therapeutic methods
|
|
DE60232742D1
(de)
|
2001-10-04 |
2009-08-06 |
Immunex Corp |
Ul16-bindungsprotein 4
|
|
KR100900249B1
(ko)
|
2001-12-07 |
2009-05-29 |
포항공과대학교 산학협력단 |
ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
|
|
NZ536420A
(en)
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
US8927251B2
(en)
|
2002-10-07 |
2015-01-06 |
The University Of Chicago |
Targeting of herpes simplex virus to specific receptors
|
|
BRPI0315295C1
(pt)
|
2002-10-17 |
2021-05-25 |
Genmab As |
anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
|
|
US7563869B2
(en)
*
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
PL1897548T5
(pl)
|
2003-02-28 |
2025-03-17 |
The Johns Hopkins University |
Regulacja komórek T
|
|
US20060246123A1
(en)
|
2003-03-12 |
2006-11-02 |
Eli Gilboa |
Oligonucleotide mimetics
|
|
US7473418B2
(en)
|
2004-03-25 |
2009-01-06 |
Cell Genesys, Inc. |
Pan cancer oncolytic vectors and methods of use thereof
|
|
BRPI0509274A
(pt)
|
2004-03-26 |
2007-09-04 |
Pfizer Prod Inc |
usos de anticorpos anti-ctla-4
|
|
KR101295733B1
(ko)
|
2004-08-20 |
2013-08-13 |
비랄리틱스 리미티드 |
혈액암의 치료방법 및 조성물
|
|
US20090252741A1
(en)
|
2004-09-08 |
2009-10-08 |
Ohio State University Research Foundation |
Human monoclonal anti-ctla4 antibodies in cancer treatment
|
|
AU2005302408B2
(en)
|
2004-10-28 |
2012-08-09 |
The Government of the United States of America as represented by the Department of Veterans Affairs |
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
|
|
EP1843773A4
(en)
|
2005-01-17 |
2008-07-30 |
Viralytics Ltd |
METHOD AND COMPOSITION FOR TREATING NEOPLASIA
|
|
CA2609142C
(en)
|
2005-05-27 |
2016-02-09 |
Fondazione Centro San Raffaele Del Monte Tabor |
Therapeutic gene vectors comprising mirna target sequences
|
|
CA2611861C
(en)
|
2005-06-08 |
2017-11-28 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for the treatment of persistent infections
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
HRP20150175T1
(en)
|
2005-12-16 |
2015-03-27 |
Amgen Research (Munich) Gmbh |
Means and methods for the treatment of tumorous diseases
|
|
RU2008129827A
(ru)
|
2005-12-21 |
2010-01-27 |
МЕДИММЬЮН, ЭлЭлСи (US) |
МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
WO2007123737A2
(en)
|
2006-03-30 |
2007-11-01 |
University Of California |
Methods and compositions for localized secretion of anti-ctla-4 antibodies
|
|
AU2007266306A1
(en)
|
2006-05-26 |
2007-12-06 |
Apollo Life Sciences Limited |
An isolated IL-12 molecule or chimeric molecules thereof
|
|
CN101104640A
(zh)
|
2006-07-10 |
2008-01-16 |
苏州大学 |
抗人pd-l1单克隆抗体制备及应用
|
|
JP2008066402A
(ja)
|
2006-09-05 |
2008-03-21 |
Fujifilm Corp |
撮像素子および撮像装置
|
|
WO2009016433A2
(en)
*
|
2006-09-15 |
2009-02-05 |
Ottawa Health Research Institute |
Oncolytic rhabdovirus
|
|
US20100111873A1
(en)
|
2007-02-20 |
2010-05-06 |
Russell Stephen J |
Treating cancer with viral nucleic acid
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
US20110027310A1
(en)
*
|
2007-05-04 |
2011-02-03 |
Medin Jeffrey A |
Compositions and Methods for Cancer Treatment
|
|
EP2144632B1
(en)
|
2007-05-09 |
2016-11-16 |
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College |
Synthetic herpes simplex viruses type-1 for treatment of cancers
|
|
EP2212350B1
(en)
|
2007-10-26 |
2013-08-28 |
Governing Council of the University of Toronto |
Treating chronic viral infection by targetting TIM-3
|
|
WO2009100140A1
(en)
|
2008-02-04 |
2009-08-13 |
Medarex, Inc. |
Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
|
|
WO2009111892A1
(en)
|
2008-03-14 |
2009-09-17 |
Ottawa Health Research Institute |
Microrna mediated oncolytic targeting
|
|
NO2700405T3
(https=)
|
2008-05-29 |
2018-09-01 |
|
|
|
WO2009148488A2
(en)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Use of oncolytic herpes viruses for killing cancer stem cells
|
|
GB0810912D0
(en)
|
2008-06-13 |
2008-07-23 |
Inst Animal Health Ltd |
Vector
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
JP2012520085A
(ja)
|
2009-03-13 |
2012-09-06 |
エーゲン、インコーポレイテッド |
生物活性ｒｎａの送達のための組成物及び方法
|
|
ES2385251B1
(es)
*
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
US20100297072A1
(en)
|
2009-05-19 |
2010-11-25 |
Depinho Ronald A |
Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
|
|
EP2555778A4
(en)
|
2010-04-06 |
2014-05-21 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
|
|
US20130071430A1
(en)
|
2010-04-09 |
2013-03-21 |
The University Of Tokyo |
Microrna-controlled recombinant vaccinia virus and use thereof
|
|
WO2011130749A2
(en)
|
2010-04-16 |
2011-10-20 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
WO2012006181A2
(en)
|
2010-06-29 |
2012-01-12 |
Mount Sinai School Of Medicine |
Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
|
|
CA2806021C
(en)
|
2010-08-13 |
2019-05-21 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
RS58146B1
(sr)
*
|
2011-09-08 |
2019-02-28 |
Univ New York |
Onkolitički herpes simpleks virus i njegova terapeutska upotreba
|
|
US11951157B2
(en)
|
2011-10-11 |
2024-04-09 |
Universitat Zurich |
Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
|
|
EP2591796A1
(en)
|
2011-11-10 |
2013-05-15 |
Universität Zürich |
Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
|
|
EP2766035B1
(en)
|
2011-10-11 |
2018-03-28 |
Universität Zürich Prorektorat MNW |
Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
|
|
EP4079319A1
(en)
|
2011-10-17 |
2022-10-26 |
IO Biotech ApS |
Pd-l1 based immunotherapy
|
|
US20130156808A1
(en)
|
2011-11-22 |
2013-06-20 |
Stipan Jonjic |
Vaccine comprising beta-herpesvirus
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
WO2013112942A1
(en)
|
2012-01-25 |
2013-08-01 |
Dna Trix, Inc. |
Biomarkers and combination therapies using oncolytic virus and immunomodulation
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
US20150250837A1
(en)
*
|
2012-09-20 |
2015-09-10 |
Morningside Technology Ventures Ltd. |
Oncolytic virus encoding pd-1 binding agents and uses of the same
|
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
WO2014138314A1
(en)
*
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Oncolytic virus
|
|
WO2014138306A1
(en)
*
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
DK2986311T3
(en)
|
2013-04-18 |
2019-02-25 |
Tilt Biotherapeutics Oy |
IMPROVED ADOPTIVE CELL THERAPY
|
|
US20160163211A1
(en)
|
2013-05-16 |
2016-06-09 |
Pearson Education, Inc. |
Accessible content publishing engine
|
|
BR112016009465A8
(pt)
|
2013-10-28 |
2018-01-30 |
Univ Pittsburgh Commonwealth Sys Higher Education |
vetor de hsv oncolítico.
|
|
EP3110443A4
(en)
|
2014-02-27 |
2017-11-15 |
Viralytics Limited |
Combination method for treatment of cancer
|
|
RU2696312C2
(ru)
*
|
2014-07-16 |
2019-08-01 |
Трансген Са |
Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
|
|
JP6810687B2
(ja)
|
2014-10-08 |
2021-01-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｆａｐ及びｄｒ５に特異的な二重特異性抗体と化学療法剤との併用療法
|
|
CA2973720A1
(en)
*
|
2015-01-14 |
2016-07-21 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
ES2994611T3
(en)
|
2015-10-19 |
2025-01-27 |
Cg Oncology Inc |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
BR112018012180A2
(pt)
*
|
2015-12-17 |
2018-12-04 |
Psioxus Therapeutics Ltd |
vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
|
|
US10612005B2
(en)
|
2016-01-08 |
2020-04-07 |
Replimune Limited |
Modified oncolytic virus
|
|
KR20180136435A
(ko)
|
2016-01-27 |
2018-12-24 |
온코루스, 인크. |
종양 살상형 바이러스 벡터 및 그의 용도
|
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
|
AU2017290828A1
(en)
|
2016-06-30 |
2019-01-24 |
Virogin Biotech Canada Ltd |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
ES2972406T3
(es)
|
2016-08-01 |
2024-06-12 |
Virogin Biotech Canada Ltd |
Vectores del virus oncolítico del herpes simple que expresan moléculas estimuladoras del sistema inmunitario
|
|
JP2019527737A
(ja)
|
2016-08-09 |
2019-10-03 |
アルケヤール， アルモハナッドＡＬＫＡＹＹＡＬ， Ａｌｍｏｈａｎａｄ |
Ｉｌ１２を発現する腫瘍溶解性ラブドウイルス
|
|
WO2018049248A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus equipped with bispecific engager molecules
|
|
US20190275092A1
(en)
|
2016-11-01 |
2019-09-12 |
Dnatrix, Inc. |
Combination therapy for treatment of brain cancers
|
|
US11298420B2
(en)
|
2016-12-21 |
2022-04-12 |
Memgen, Llc |
Armed oncolytic viruses
|
|
KR20190098215A
(ko)
|
2016-12-21 |
2019-08-21 |
멤젠 엘엘씨 |
무장된 복제-가능 종양 분해 아데노바이러스
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|